ITGAE

Across TCGA pan-cancer cohorts, ITGAE Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ITGAE data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ITGAE Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ITGAE expression acts as an unfavorable survival marker.

MESO, UCS, and KICH are the cancer types where ITGAE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	III,IV	0.077	0.580	<.001	42	view →
UCS	OS	Median	All	0.135	0.687	.009	24	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
BRCA	OS	Median	All	0.654	0.924	.007	10	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	All	0.219	0.661	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ITGAE–MESO (OS)

Open the MESO breakdown →